Variation in endometrial thickening in women with amenorrhea on tamoxifen

Breast Cancer Research and Treatment

Volumn 48, Issue 1, 1998, Pages 81-85

  Chang, J ^a,b   Powles, T J ^a,b,c   Ashley, S E ^a,b   Iveson, T ^a,b   Gregory, R K ^a,b   Dowsett, M ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Amenorrhea; Endometrial cancer; Endometrial thickening; Plasma estradiol; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTRADIOL; FOLLITROPIN; TAMOXIFEN;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THICKNESS; TRANSVAGINAL ECHOGRAPHY;

AMENORRHEA; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 0031929624     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005999008736     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group E: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 1992
2. Powles TJ, Hickish T: Tamoxifen therapy and carcinogenic risk (Editorial). J Natl Cancer Inst 87(18): 1343-1344, 1995
3. Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363, 1992
4. White I, de Matteis F, Davies A, et al.: Genotoxic potential of tamoxifen and analogues in female Fisher 344/n rats, DBA/2 and C57B2/6 mice, and in human MCL/5 cells. Carcinogenesis 13: 2197-2203, 1992
5. Phillips D, Potter G, Horton M, et al.: Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15: 1487-1492, 1994
6. Fornander T, Hellstrom A, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850-1855, 1993
7. Carmichael P, Ugwumadu A, Neven P, Hewer A, Poon G, Phillips DH: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56(7): 1475-1479, 1996
8. van Leeuwen FE, Benraadt J, Coebergh JWW, et al.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994
9. Grady D, Gebretsadik T, Kerlikowske K, et al.: Hormone replacement therapy and endometrial cancer: a meta-analysis. Obstet Gynaecol 85: 304-313, 1995
10. Ismail S: The pathology of tamoxifen-treated endometrium. J Clin Pathol 47: 827-833, 1994
11. De Muylder X, Neven P, Desomer M, et al.: Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36: 127-130, 1991
12. Cohen I, Rosen D, Shapiro J, et al.: Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 100: 567-570, 1993
13. Neven P, De Muylder X, Van Belle Y, et al.: Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynaecol Reprod Bio 35: 235-238, 1990
14. Neven P: Tamoxifen and endometrial lesions. Lancet 342: 452, 1993
15. Aleem F, Predanic M: Endometrial changes in patients on tamoxifen. Lancet 346: 1292-1293, 1995
16. Lahty E, Blanco G, Kauppila A, et al.: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynaecol 81: 660-664, 1993
17. Cross S, Ismail S: Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report. Br J Obstet Gynaecol 97: 190-192, 1990
18. Potischman N, Hoover R, Brinton L, et al.: Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88: 1127-1135, 1996
19. Kedar R, Bourne T, Powles T, et al.: Effects of tamoxifen on the uterus and ovaries of women involved in a randomised breast cancer prevention trial. Lancet 343: 1318-1321, 1994
20. Powles T, Tillyer C, Jones A, et al.: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680-684, 1990
21. Powles TJ, Jones AL, Ashley SE, et al.: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82, 1994
22. Dowsett M, Goss P, Powles T: Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 14: 1957-1961, 1987
23. Fornander T, Rutqvist LE, Cedermark B, et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i: 117-120, 1989
24. Andersson M, Storm H, Mouridsen H: Incidence of new primary cancers after adjuvant tamoxifen and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013-1017, 1991
25. Cummings F, Gray R, Tormey D: Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long term follow-up and causes of death. J Clin Oncol 11(1): 29-35, 1993